Best of ASCO - 2014 Annual Meeting

 

Welcome

Adjuvant Therapy

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2017 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A novel MAGE-A1-IgG antibody for lung adenocarcinoma.

Yuan Mao

e20085

A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.

Heather A. Wakelee

TPS8576

Adjuvant chemotherapy outcome in unselected single-center non-small cell lung cancer (NSCLC) population.

Marie Florescu

e20089

Amenorrhea in lung cancer patients.

Elizabeth Jane Cathcart-Rake

e20092

Apatinib to enhance antitumor activity of gefitinib in non-small cell lung cancer.

Fang Li

e20086

Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.

Patrick M. Forde

TPS8577

Distant outcomes of chemoimmunotherapy with recombinant interferon-gamma for acinar-type adenocarcinoma of the lung.

Sergey P. Pyltsin

e20090

Dual time PET-CT for mediastinal nodal staging in patients diagnosed with non-small cell lung cancer in an area with high prevalence of infectious granulomatous disease (LACOG-0114).

Bruno Hochhegger

e20083

EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.

Jamie E. Chaft

TPS8575

Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment.

S.P. Somashekhar

8527

Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).

Yi-Long Wu

8500

Histological features and survival in NSCLC patients treated with surgery with curative intention.

Nuria Cárdenas Quesada

e20080

Long-term survival in patients with NSCLC treated with single fraction vs multi-fraction palliative radiotherapy in the case of lung tumor, brain metastases, and bone metastases.

Sylwia Szablewska

e20082

Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results.

Florence Atrafi

8530

Priming PD-L1 expression by chemotherapeutic agents in non-small cell lung cancers.

Emily Pei-Ying Lin

e20087

Spatio-temporal distribution of lung cancer mortality rate in Peru: 2005-2014.

Claudio J. Flores

e20081

Survival benefit of systemic chemotherapy given as adjuvant (ACT) after thoracic surgery for N0-1 non-small cell lung cancer (NSCLC) patients (pts) with synchronous brain metastasis (SBM).

Sarah Shin

8525

The impact of four dimensions CT simulation on planning target volume in radiotherapy for primary lung cancer.

Fawzi Jamil Abuhijla

e20091

The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: A decision, effectiveness, and cost-effectiveness analysis.

Jessica Lynn Hudson

8526

The role of adjuvant therapy in the management of resected large cell neuroendocrine carcinoma (LCNEC) of the lung: A National Cancer Database (NCDB) analysis.

Lara Ann Kujtan

8529

Typical bronchial NETs as a misleading biology.

Dalvinder Mandair

8528